Physician profile
Mark E Krebs
NPI 1487653945
$5,507.68
in general payments reported to CMS, 2019-2025
25 companies · $624 in 2025
The $624 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $253 · 2021: $312 · 2022: $518 · 2023: $1,802 · 2024: $566 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966 · Travel and Lodging: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.22 |
| Travel and Lodging | $1,025.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,557.66 | 2019-2025 | Watchman Flx, Watchman Access System, Rhythmia Mapping System |
| Stereotaxis INC | $873.24 | 2019 | |
| Amgen INC. | $685.11 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $230.38 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $141.84 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $125.71 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $106.65 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.83 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $97.31 | 2024-2025 | Wegovy |
| Pfizer INC. | $91.34 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $83.65 | 2023-2025 | Onpattro |
| Medtronic, INC. | $77.88 | 2023 | Arctic Front Advance |
| Amarin Pharma, INC. | $68.10 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $52.36 | 2019 | |
| Abiomed | $31.66 | 2024 | Impella |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $28.32 | 2025 | Wainua |
| Kestra Medical Technology Services, INC. | $25.50 | 2025 | Assure Wcd |
| Medicomp INC | $20.00 | 2023 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $18.91 | 2024 | Nexletol |
| Lilly USA, LLC | $18.85 | 2025 | Zepbound |
| Astellas Pharma US INC | $16.71 | 2021 | |
| Biosense Webster, INC. | $15.07 | 2024 | Carto 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.54 | 2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $11.10 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $9.96 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Krebs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.